News - Bristol-Myers Squibb, sofosbuvir

Filter

Popular Filters

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

16-01-2014

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans…

Anti-viralsBristol-Myers SquibbdaclatasvirGilead SciencesPharmaceuticalResearchsofosbuvir

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24-04-2013

Among a number of drug and biotech majors planning to present at the 2013 annual meeting of the European…

AbbVieAnti-viralsasunaprevirBiotechnologyBristol-Myers SquibbdaclatasvirGilead SciencesJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Back to top